Abstract
Analysis of pathological data in the 10th year of follow-up of a multicentre trial of the management of operable breast cancer has confirmed the correlation of prognosis with tumour grade, tumour size and lymph-node status. For each factor examined there was no difference in survival between the 2 treatment groups ("watch policy" and radiotherapy) but patients in the WP group whose tumours were of Grade II or III or greater than 2 cm, or with lymph-node metastases, had a greater chance of local recurrence. Cellular reaction had no relationship with prognosis, except in patients with Grade III tumours. The clinical relevance and application of these results are discussed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Elston, C., Gresham, G., Rao, G. et al. The cancer research campaign (King's/Cambridge trial for early breast cancer: Clinico-pathological aspects. Br J Cancer 45, 655–669 (1982). https://doi.org/10.1038/bjc.1982.106
Issue Date:
DOI: https://doi.org/10.1038/bjc.1982.106
- Springer Nature Limited
This article is cited by
-
Effect of specialized diagnostic assessment units on the time to diagnosis in screen-detected breast cancer patients
British Journal of Cancer (2015)
-
Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis
Genome Biology (2013)
-
Morphometrical malignancy grading is a valuable prognostic factor in invasive ductal breast cancer
British Journal of Cancer (2002)
-
In situ cytokine production by breast cancer tumor-infiltrating lymphocytes
Annals of Surgical Oncology (1996)
-
The Immunology of Breast Cancer
Clinical Immunotherapeutics (1995)